Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Warner Chilcott Reports First Quarter Loss, Big Revenue Leap

By Pharmaceutical Processing | May 7, 2010

Warner Chilcott reported a $17.2 million loss for the first quarter today, even though revenue tripled, after the Irish drug developer bought a prescription drug business from Procter & Gamble Co.

The company said the loss amounted to 7 cents per share in the quarter that ended March 31. That compares with net income of $43.3 million, or 17 cents per share, in 2009’s first quarter.

Revenue soared to $761.3 million from $245.9 million due mainly to products acquired from P&G. Adjusted income, which does not include the accounting adjustment and other one-time items, was 88 cents per share.

Analysts polled by Thomson Reuters expected, on average, earnings of 86 cents per share on $764.8 million in revenue. Analysts normally exclude one-time items from their estimates.

Warner Chilcott acquired the global branded prescription drug business of P&G last fall. The company said products from that deal contributed $478.3 million in revenue for the first quarter. They include the osteoporosis drug Actonel and Enablex, a treatment for overactive bladders.

The company said it incurred a $93.7 million expense due to an accounting adjustment that boosted the opening value of inventories it acquired from P&G. Selling, general and administrative expenses increased to $320.1 million from $46.8 million in the quarter, and research and development rose about 31 percent to $31.1 million.

Warner Chilcott Plc. also said it had a $24.6 million gain from the sale of some inventories to LEO Pharma A/S.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE